EUCTR2020-000761-16-DE进行中（未招募）1 期
A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab inAddition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age)with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation(HSCT) - Ravulizumab in Pediatric Participants with TMA after HSCT
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. = 28 days of age up to < 18 years of age at the time of signing the informed consent
- •2. Participants who received HSCT within the past 12 months at the time of Screening
- •3. A TMA diagnosis, based on meeting all of the following criteria during the Screening Period and/or = 14 days prior to the Screening Period:
- •De novo thrombocytopenia or platelet transfusion refractoriness:
- •Any one of the following markers of hemolysis:
- •-Lactate dehydrogenase > ULN for age,
- •- Presence of schistocytes = 2 high power field (HPF) or = 1% in peripheral blood smear
- •Proteinuria on spot urinalysis
- •De novo anemia OR presence of hypertension
- •4. Participants must have HSCT-TMA that persists for at least 72 hours after initial management of any triggering agent/condition
- •5.Body weight = 5 kg at Screening or =7 days prior to the start of the Screening Period (date of consent)
- •6. Male or female Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- •7. Vaccinated against meningococcal infections if clinically feasible, according to institutional guidelines for immune reconstitution after HSCT. Participants must be re-vaccinated against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae if clinically feasible, according to institutional guidelines for immune reconstitution after HSCT. All participants should be administered coverage with prophylactic antibiotics according to institutional posttransplant infection prophylaxis guidances including coverage against N. meningiditis for at least 2 weeks after meningococcal vaccination. Participants who cannot receive meningococcal vaccine should receive antibiotic prophylaxis coverage against N. meningiditis the entire Treatment Period and for 8 months following the final dose of ravulizumab.
- •8. Participants or their legally authorized representative must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent or assent form and in this protocol
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 40
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Known familial or acquired ‘a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13’ (ADAMTS13) deficiency (activity < 5%)
- •2. Known Shiga toxin-related hemolytic uremic syndrome (ST-HUS)
- •3. Positive direct Coombs test
- •4. Clinical diagnosis or suspicion of disseminated intravascular coagulation (DIC)
- •5. Known bone marrow/graft failure
- •6. Diagnosis of veno-occlusive disease (VOD)
- •7. Human immunodeficiency virus (HIV) infection (evidenced by HIV-1 or HIV-2 antibody titer,
- •8. Unresolved meningococcal disease
- •9. Presence or suspicion of sepsis (treated or untreated) within 7 days prior to Screening
- •10. Pregnancy or breastfeeding
- •11. Hypersensitivity to murine proteins or to 1 of the excipients of ravulizumab
- •12. Previously or currently treated with a complement inhibitor
研究者
相似试验
招募中
1 期
A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to <18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)Hematopoietic stem cell transplant-associated thrombotic microangiopathy(HSCT- TMA)MedDRA version: 20.0Level: SOCClassification code: 10005329Term: Blood and lymphatic system disorders Class: 3CTIS2023-507850-33-00Alexion Pharmaceuticals Inc.40
进行中（未招募）
1 期
Study of ravulizumab in pediatric participants with HSCT-TMAhematopoietic stem cell transplant-associated thrombotic microangiopathyMedDRA version: 20.0Level: PTClassification code 10043645Term: Thrombotic microangiopathySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2020-000761-16-ITALEXION PHARMACEUTICALS INCORPORATED40
进行中（未招募）
1 期
Study of ravulizumab in pediatric participants with HSCT-TMAhematopoietic stem cell transplant-associated thrombotic microangiopathyMedDRA version: 20.0Level: PTClassification code 10043645Term: Thrombotic microangiopathySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2020-000761-16-FRAlexion Pharmaceuticals, Inc.40
招募中
3 期
Study of Ravulizumab in Pediatric Participants With HSCT-TMAJPRN-jRCT2071200070Yokosawa Jun40
进行中（未招募）
1 期
Study of ravulizumab in pediatric participants with HSCT-TMAhematopoietic stem cell transplant-associated thrombotic microangiopathyMedDRA version: 20.0Level: PTClassification code 10043645Term: Thrombotic microangiopathySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2020-000761-16-GBAlexion Pharmaceuticals, Inc.40